Niagen Bioscience, Inc.

Niagen Bioscience, Inc. (NASDAQ: NAGE), formerly ChromaDex Corp., is the global leader in NAD+ (nicotinamide adenine dinucleotide) science and healthy-aging research. As a trusted pioneer of NAD+ discoveries, Niagen Bioscience™ is dedicated to advancing healthspan through precision science and innovative NAD+-boosting solutions. The Niagen Bioscience team, composed of world-renowned scientists, works with independent investigators from esteemed universities and research institutions around the globe to uncover the full potential of NAD+. A vital coenzyme found in every cell of the human body, NAD+ declines with age and exposure to everyday lifestyle stressors. NAD+ depletion is a key contributor to age-related changes in health and vitality.

Current securities

1. 10-Q filingAug 4, 2026
2. Results of Operations and Financial Condition · Regulation FD DisclosureAug 4, 2026
3. 424B5 filingJul 10, 2026
4. EFFECT filingJul 9, 2026
5. Submission of Matters to a Vote of Security HoldersJun 29, 2026